AMRN 最新10-Q变化
将 AMRN 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-28 与上一份 10-Q · 2026-07-29
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +33 | −35 | ~29 | 57 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 2 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-28
In August 2026, the Saudi Heart Association released a focused update; Guidelines on Best Practices in the Management of Chronic Coronary Syndromes, or CCS. The update stated the addition of IPE should be considered for statin-treated CCS patients with persistently elevated TGs (135-499 mg / dL) and…
In August 2026, the iCARDIO Alliance released Global Implementation Guidelines on Ischemic Heart Disease, or IHD, stating in the treatment of chronic IHD – lipid management, IPE (2-grams twice daily) may be used in patients with IHD and hypertriglyceridemia (>150 mg/dL).
In August 2026, the European Society of Cardiology, or ESC, released Guidelines for the Management of CV Disease and Chronic Kidney Disease, in collaboration with the European Renal Association, or ERA. The release stated treatment with IPE as add-on therapy to a statin may be considered in patients…
In September 2026, the U.S. Department of Veterans Affairs and U.S. Department of Defense published a synopsis of its 2025 Clinical Practice Guideline for Lipid Management for CV Disease Risk Reduction. The synopsis suggests using IPE, as a secondary prevention, in patients on statin therapy with pe…
In July 2026, at the Schlieren Research meeting, researchers from the University of Zurich in collaboration with Amarin presented data on the effects of IPE on circulating tissue factor from both a mechanistic perspective and insights from within REDUCE-IT.
相对上期删除的文字 · 来源:10-Q · 2026-07-29
In April 2026, the European Federation of Internal Medicine released Assessment and Management of Cardiovascular–Kidney–Liver Metabolic-Syndrome in the Primary Care Setting: A Multidisciplinary Consensus Statement, in the European Journal of Internal Medicine. This stated that treatment of elevated …
In May 2026, the American Heart Association, or AHA, released a 2026 Scientific Statement update on the Secondary Prevention After Coronary Artery Bypass Graft Surgery, which stated that as a third line therapy if the combination of statin and ezetimibe still fails to achieve the target Low-Density …
In June 2026, the American College of Cardiology/AHA Joint Committee released a report; the 2026 AHA/American College of Cardiology, or ACC/American Diabetes Association, or ADA/American Society of Nephrology, or ASN, Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascu…
In May 2026, at the Digestive Disease Week meeting in Chicago, IL, researchers from Harvard working on an Amarin supported investigator-initiated trial presented data at a poster session. The poster presentation included data on the effect of IPE treatment on fecal metabolites and microbiome among p…
In May 2026, at the European Atherosclerosis Society meeting in Athens, Greece, global collaborators presented two Amarin supported oral E-poster presentations. The first presentation reported data on how risk-weighted apolipoprotein B compares to traditional lipid biomarkers in predicting residual …
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议